A Phase 2, Open-Label, Single-Arm, Sequential-Panel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Posaconazole (POS, MK-5592) Intravenous and Powder for Oral Suspension Formulations in Pediatric Participants From Birth to Less Than 2

This study aims to estimate the pharmacokinetics of posaconazole (POS, MK-5592) intravenous and powder for oral suspension formulations in pediatric participants 2 years of age and younger with invasive fungal infection.

View full study on ClinicalTrials.gov